Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC

  • STATUS
    Recruiting
  • participants needed
    30
  • sponsor
    H. Lee Moffitt Cancer Center and Research Institute
Updated on 7 December 2022
radical cystectomy
carcinoma
neutrophil count
nivolumab
bladder tumor
cg0070

Summary

Investigators will evaluate the safety and efficacy of combination neoadjuvant therapy using intravesical CG0070 and IV Nivolumab in cisplatin ineligible patients with Muscle Invasive Bladder Cancer (MIBC).

Details
Condition Muscle-Invasive Bladder Carcinoma, Bladder Cancer
Treatment Nivolumab, CG0070
Clinical Study IdentifierNCT04610671
SponsorH. Lee Moffitt Cancer Center and Research Institute
Last Modified on7 December 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note